Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis
ZX Qu, N Pliskin, MW Jensen, D White… - Archives of …, 2001 - jamanetwork.com
Background Interferon beta treatment is only partially effective in multiple sclerosis (MS)
suggesting a potential role for adjunctive therapies. Retinoids can augment the clinical
efficacy of type 1 interferons in patients with cancer. We reasoned that the same might hold
in MS. Interferon beta-1b added to peripheral blood mononuclear cells in vitro partially
reverses the CD8 suppressor cell defect of patients with MS. All-transretinoic acid added to
peripheral blood mononuclear cells from untreated patients with MS or from controls …
suggesting a potential role for adjunctive therapies. Retinoids can augment the clinical
efficacy of type 1 interferons in patients with cancer. We reasoned that the same might hold
in MS. Interferon beta-1b added to peripheral blood mononuclear cells in vitro partially
reverses the CD8 suppressor cell defect of patients with MS. All-transretinoic acid added to
peripheral blood mononuclear cells from untreated patients with MS or from controls …